Skip to main content
SpringerLink
Log in

Tuberculosis

  • Chapter
Management of Antimicrobials in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

  • 212 Accesses

Abstract

In 1990, approx 1.7 billion persons, or one-third of the world’s population, was infected with Mycobacterium tuberculosis (1). Tuberculosis (TB) remains the largest cause of death from infectious diseases, with 3 million deaths worldwide each year (2). The mortality rate has steadily declined since it peaked at 400/100,000 in 1750, in association with migration to cities during the Industrial Revolution (3). When streptomycin was introduced in 1946, the mortality rate was 33/100,000. By 1993, the mortality rate in the United States had declined to less than 1/100,000 (4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Hlth Org 1992; 709: 149–159.

    Google Scholar 

  2. Reichman LB. Defending the public’s health against tuberculosis. JAMA 1997; 278: 865–867.

    Article  PubMed  CAS  Google Scholar 

  3. Youmans GP. Tuberculosis. Philadelphia: WB Sanders, 1979.

    Google Scholar 

  4. CDC (Centers for Disease Control and Prevention). Reported tuberculosis in the United States, 1993, October, 1994, pp. 1–42.

    Google Scholar 

  5. Heifets LB, Good RC. Current laboratory methods for the diagnosis of tuberculosis. In: Bloom BR (ed) Tuberculosis: Pathogenesis, Protection, and Control, 1st edit. Washington, DC: American Society for Microbiology, 1994, pp. 85–109.

    Google Scholar 

  6. Moore M, Onorato IM, McCray E, et al. Trends in drug-resistant tuberculosis in the United States, 1993–1996. JAMA 1997; 278: 833–837.

    Article  PubMed  CAS  Google Scholar 

  7. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med 1998; 338: 1641–1649.

    Article  PubMed  CAS  Google Scholar 

  8. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can’t afford not to try it. N Engl J Med 1993; 328: 576–578.

    Article  PubMed  CAS  Google Scholar 

  9. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423–430.

    PubMed  CAS  Google Scholar 

  10. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–532.

    Article  PubMed  CAS  Google Scholar 

  11. Simone PM, Dooley SW. Multidrug-resistant.

    Google Scholar 

  12. Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York city multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275: 452–457.

    Article  PubMed  CAS  Google Scholar 

  13. Agerton T, Valway S, Gore B, et al. Transmission of a highly drug-resistant strain (strain W-1) of Mycobacterium tuberculosis. Community outbreak and nosocomial transmission via a contaminated bronchoscope. JAMA 1997; 278: 1073–1077.

    Article  PubMed  CAS  Google Scholar 

  14. Ussery XT, Bierman JA, Valway SE et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons exposed in a medical examiner’s office, New York. Infect Control Hosp Epidemiol 1995; 16: 160–165.

    Article  PubMed  CAS  Google Scholar 

  15. Kenyon TA, Valway SE, Ihle WW, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med 1996; 334: 933–938.

    Article  PubMed  CAS  Google Scholar 

  16. Ikeda RM, Birkhead GS, DeFerdinando Jr. GT, et al. Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs. Infect Control Hosp Epidemiol 1995; 16: 152–159.

    Article  PubMed  CAS  Google Scholar 

  17. Altamirano M, Marostenmaki J, Wong A, et al. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis 1994; 169: 1162–1165.

    Article  PubMed  CAS  Google Scholar 

  18. Bodmer T, Zurcher G, Imboden P, et al. Mutation position and type of substitution in the b-subunit of RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobaterium tuberculosis. J Antimicrob Chemother 1995; 35: 345–348.

    Article  PubMed  CAS  Google Scholar 

  19. Cambau E, Sougakoff W, Besson M, et al. Selection of gyrA mutant Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479–483.

    Article  PubMed  CAS  Google Scholar 

  20. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784–791.

    Article  PubMed  CAS  Google Scholar 

  21. Shimao T. Drug resistance in tuberculosis control. Tubercle 1987; 68: 5–10.

    Article  PubMed  CAS  Google Scholar 

  22. ATS. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359–1374.

    Article  Google Scholar 

  23. Byrd RB, Horn BR, Solomon DA, et al. Treatment of tuberculosis by the nonpulmonary physician. Ann Intern Med 1977; 86: 799–802.

    Article  PubMed  CAS  Google Scholar 

  24. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquistion of drug resistance. JAMA 1993; 270: 65–68.

    Article  PubMed  CAS  Google Scholar 

  25. Evans ME, Perkins DJ, Simmons GD. Tuberculosis management practices in Kentucky: comparison with national guidelines. South Med J 1999; 92: 375–379.

    Article  PubMed  CAS  Google Scholar 

  26. Cohn DL. Treatment of multidrug-resistant tuberculosis. J Hosp Infect 1995; 30: S322 - S328.

    Article  Google Scholar 

  27. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219–225.

    Article  PubMed  CAS  Google Scholar 

  28. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665–671.

    Article  PubMed  CAS  Google Scholar 

  29. Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951–954.

    Article  PubMed  CAS  Google Scholar 

  30. Vernon A. Update on US Public Health Service study 22: a trial of once weekly isoniazid and rifapentine in the continuation phase of TB treatment. Am J Respir Crit Care Med 1998; 157: A467.

    Google Scholar 

  31. Pulido F, Pena J-M, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157: 227–232.

    Article  PubMed  CAS  Google Scholar 

  32. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47: 1–58.

    Google Scholar 

  33. Narita M, Ashkin D, Hollender ES, Pitchenick AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157–161.

    Article  PubMed  CAS  Google Scholar 

  34. CDC. Initial therapy for tuberculosis in the era of multidrug resistance. MMWR 1993; 42: 1–8.

    Google Scholar 

  35. World Health Organization. DOTS: Directly observed treatment, short course.

    Google Scholar 

  36. Bloch AB, Simone PM, McCray E, et al. Preventing multidrug-resistant tuberculosis. JAMA 1996; 275: 487–489.

    Article  PubMed  CAS  Google Scholar 

  37. Evans ME, Finger R. Current recommendations for empiric therapy of tuberculosis. J Kentucky Med Assoc 1997; 95: 290.

    CAS  Google Scholar 

  38. Goble M. Drug-resistant tuberculosis. Semin Resp Infect 1986; 1: 220–229.

    CAS  Google Scholar 

  39. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289–293.

    Article  PubMed  CAS  Google Scholar 

  40. Alangaden GJ, Lerner SA. The clinical uses of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213–1221.

    Article  PubMed  CAS  Google Scholar 

  41. Hong Kong Chest Service BMRC. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin, and rifampicin. Tuberc Lung Dis 1992; 73: 59–67.

    Article  Google Scholar 

  42. Rastogi N, Labrousse V, Goh KS. In-vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167–175.

    Article  PubMed  CAS  Google Scholar 

  43. Penoquin CA. Using therapeutic drug monitoring to dose the antimycrobacterial drugs. Clin Chest Med 1997; 18: 79–87.

    Article  Google Scholar 

  44. Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis 1981; 123: 262–264.

    PubMed  CAS  Google Scholar 

  45. Treasure RL, Seaworth BJ. Current role of surgery in Mycobacterium tuberculosis. Ann Thorac Surg 1995; 59: 1405–1409.

    Article  PubMed  CAS  Google Scholar 

  46. Pomerantz M, Madsen L, Goble M, et al. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 42: 1108–1112.

    Article  Google Scholar 

  47. Pomerantz M, Brown JM. Surgery in the treatment of multidrug-resistant tuberculosis. Clin Chest Med 1997; 18: 123–130.

    Article  PubMed  CAS  Google Scholar 

  48. Van Leuven M, DeGroot M, Shen KP, et al. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997; 63: 1368–1373.

    Article  PubMed  Google Scholar 

  49. Jordan TJ, Lewit EM, Montgomery RL, et al. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers: a decision analysis. JAMA 1991; 265: 2987–2991.

    Article  PubMed  CAS  Google Scholar 

  50. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137–1144.

    Article  PubMed  CAS  Google Scholar 

  51. Turett GS, Fazal BA, Justman JE, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis. Clin Infect Dis 1997; 24: 513–514.

    Article  PubMed  CAS  Google Scholar 

  52. CDC. The use of preventive therapy for tuberculosis infection in the United States. Recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR 1990; 39: 9–12.

    Google Scholar 

  53. Chaisson RE, Bishai W. Short course preventive therapy for tuberculosis in HIV-infected. 1998.

    Google Scholar 

  54. CDC. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR 1998; 47: 911–912.

    Google Scholar 

  55. CDC. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41: 1–8.

    Google Scholar 

  56. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrugresistant tuberculosis. A Delphi survey. Chest 1994; 106: 431–434.

    Article  PubMed  CAS  Google Scholar 

  57. Harkin TJ, Harris HW. Treatment of mutidrug-resistant tuberculosis. In: Rom WN, Garay SM, eds. Tuberculosis. 1st ed. Boston: Little, Brown and Company; 1996: 843–862.

    Google Scholar 

Download references

Authors
  1. Martin E. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical University of South Carolina, Charleston, SC, USA

    Arch G. Mainous III PhD

  2. College of Medicine, University of Kentucky, Lexington, KY, USA

    Claire Pomeroy MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Evans, M.E. (2001). Tuberculosis. In: Mainous, A.G., Pomeroy, C. (eds) Management of Antimicrobials in Infectious Diseases. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-036-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-036-0_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5708-8

  • Online ISBN: 978-1-59259-036-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation